These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26654975)

  • 21. Procedural and one-year clinical outcomes of bioresorbable vascular scaffolds for the treatment of chronic total occlusions: a single-centre experience.
    Özel E; Taştan A; Öztürk A; Özcan EE; Kilicaslan B; Özdogan Ö
    Cardiovasc J Afr; 2016 Nov/Dec 23; 27(6):345-349. PubMed ID: 27078224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optical Coherence Tomography for Coronary Bioresorbable Vascular Scaffold Implantation: A Randomized Controlled Trial.
    Lee SY; Kang DY; Hong SJ; Ahn JM; Ahn CM; Park DW; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Park SJ; Hong MK
    Circ Cardiovasc Interv; 2020 Jan; 13(1):e008383. PubMed ID: 32525410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performing percutaneous coronary interventions with predilatation using non-compliant balloons at high-pressure versus conventional semi-compliant balloons: insights from two randomised studies using optical coherence tomography.
    Cuculi F; Bossard M; Zasada W; Moccetti F; Voskuil M; Wolfrum M; Malinowski KP; Toggweiler S; Kobza R
    Open Heart; 2020; 7(1):e001204. PubMed ID: 32076567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data.
    Bourantas CV; Serruys PW; Nakatani S; Zhang YJ; Farooq V; Diletti R; Ligthart J; Sheehy A; van Geuns RJ; McClean D; Chevalier B; Windecker S; Koolen J; Ormiston J; Whitbourn R; Rapoza R; Veldhof S; Onuma Y; Garcia-Garcia HM
    EuroIntervention; 2015 Nov; 11(7):746-56. PubMed ID: 25308301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical results of single and multiple bioresorbable drug-eluting scaffolds for treatment of de-novo coronary artery disease.
    Markovic S; Dragomir S; Walcher D; Bernhardt P; Imhof A; Rottbauer W; Wöhrle J
    Coron Artery Dis; 2016 Nov; 27(7):561-5. PubMed ID: 27244371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry.
    Latini RA; Granata F; Ielasi A; Varricchio A; Moscarella E; Tespili M; Cortese B
    Catheter Cardiovasc Interv; 2016 Sep; 88(3):380-7. PubMed ID: 27038332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study.
    Gomez-Lara J; Diletti R; Brugaletta S; Onuma Y; Farooq V; Thuesen L; McClean D; Koolen J; Ormiston JA; Windecker S; Whitbourn R; Dudek D; Dorange C; Veldhof S; Rapoza R; Regar E; Garcia-Garcia HM; Serruys PW
    EuroIntervention; 2012 Jun; 8(2):214-24. PubMed ID: 22030265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absorb GT1 Bioresorbable Vascular Scaffold System　- 1-Year Post-Marketing Surveillance in Japan.
    Suzuki N; Kozuma K; Nakamura S; Aramaki K; Saito S; Shibata Y; Nanasato M; Fujii K; Kusano H; Ediebah D; Nakamura M
    Circ J; 2019 Nov; 83(12):2460-2465. PubMed ID: 31708522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights on acute expansion and longitudinal elongation of bioresorbable vascular scaffolds in vivo and at bench test: a note of caution on reliance to compliance charts and nominal length.
    Attizzani GF; Ohno Y; Capodanno D; Francaviglia B; Grasso C; Sgroi C; Wang W; Fujino Y; Ganocy SJ; Longo G; Tamburino CI; Di Salvo M; La Manna A; Capranzano P; Tamburino C
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):E99-E107. PubMed ID: 25154722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Side branch occlusion after bioresorbable vascular scaffold implantation: lessons from optimal coherence tomography.
    Sato K; Panoulas VF; Kawamoto H; Naganuma T; Miyazaki T; Latib A; Colombo A
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):116-8. PubMed ID: 25616826
    [No Abstract]   [Full Text] [Related]  

  • 31. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
    Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA
    JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents.
    Gomez-Lara J; Garcia-Garcia HM; Onuma Y; Garg S; Regar E; De Bruyne B; Windecker S; McClean D; Thuesen L; Dudek D; Koolen J; Whitbourn R; Smits PC; Chevalier B; Dorange C; Veldhof S; Morel MA; de Vries T; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2010 Nov; 3(11):1190-8. PubMed ID: 21087756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy.
    Tijssen RYG; Kerkmeijer LSM; Takahashi K; Kogame N; Katagiri Y; Kraak RP; Chichareon P; Modolo R; Asano T; Nassif M; Kalkman DN; Sotomi Y; Collet C; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Piek JJ; Tijssen JGP; Henriques JP; de Winter RJ; Onuma Y; Serruys PW; Wykrzykowska JJ
    Int J Cardiovasc Imaging; 2020 Apr; 36(4):565-575. PubMed ID: 31898006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Major coronary evaginations following implantation of bioresorbable vascular scaffolds - Clinical and OCT characteristics.
    Blachutzik F; Achenbach S; Marwan M; Röther J; Tröbs M; Schneider R; Nef H; Weissner M; Schlundt C
    Cardiovasc Revasc Med; 2019 Jun; 20(6):485-491. PubMed ID: 30097188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study.
    Farooq V; Gomez-Lara J; Brugaletta S; Gogas BD; Garcìa-Garcìa HM; Onuma Y; van Geuns RJ; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW
    Catheter Cardiovasc Interv; 2012 May; 79(6):880-8. PubMed ID: 22514149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged high-pressure is required for optimal stent deployment as assessed by optical coherence tomography.
    Cook JR; Mhatre A; Wang FW; Uretsky BF
    Catheter Cardiovasc Interv; 2014 Mar; 83(4):521-7. PubMed ID: 23436559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of a scoring balloon for optimal lesion preparation prior to bioresorbable scaffold implantation: a comparison with conventional balloon predilatation.
    Miyazaki T; Latib A; Ruparelia N; Kawamoto H; Sato K; Figini F; Colombo A
    EuroIntervention; 2016 Apr; 11(14):e1580-8. PubMed ID: 27056118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anatomic stabilization and functional normalization of a ruptured coronary plaque 12 months after implantation of a bioresorbable scaffold.
    Gori T; Schulz E; Münzel T
    JACC Cardiovasc Interv; 2014 May; 7(5):e47-8. PubMed ID: 24746656
    [No Abstract]   [Full Text] [Related]  

  • 39. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up.
    Gomez-Lara J; Brugaletta S; Farooq V; van Geuns RJ; De Bruyne B; Windecker S; McClean D; Thuesen L; Dudek D; Koolen J; Whitbourn R; Smits PC; Chevalier B; Morel MA; Dorange C; Veldhof S; Rapoza R; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2011 Jul; 4(7):789-99. PubMed ID: 21777888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.